Matches in Nanopublications for { <http://www.nextprot.org/nanopubs#NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._1> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._1 type RangedSequencePosition NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM.assertion.
- NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._1 type SO_0001148 NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM.assertion.
- NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._1 comment "APO-RANTES-stimulated phosphorylation reduced by 15%; APO-RANTES-stimulated phosphorylation reduced by 30-50%; when associated with A-337 or A-342 or A-349; APO-RANTES-stimulated phosphorylation reduced by 80%; when associated with A-337 and A-342 or A-349; No APO-RANTES-stimulated phosphorylation; when associated with A-337; A-342 and A349; abolishes interaction with ARRB2; when associated with S-337; S-342 and S-349." NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM.assertion.
- NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._1 SIO_000053 NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._2 NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM.assertion.
- NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._1 SIO_000053 NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM._3 NX_P51681-1_MUTAGEN_336_336.RA59m7pOhVx16O-6Xs4kNPESFq-N-ctXIgseT6jgurHxM.assertion.